Spero Therapeutics Inc Dossier - Source-backed chat

Spero Therapeutics Inc

SPRONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.35

Intrinsic Value $1.61median of 3 methodsbased on filings through 30 Jun 2026

Market Price $1.26Price as of 1 Oct 2026

UndervaluedIntrinsic value is 28% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $73.4M

Enterprise Value $22.6M

Shares Outstanding 61M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Spero Therapeutics represents a compelling, de-risked biotechnology investment following the FDA approval of Utebzi (tebipenem pivoxil) on June 17, 2026. As the first and only oral carbapenem antibiotic approved for complicated urinary tract infections (cUTIs) in adults with limited options, Utebzi addresses a massive unmet need (over 3 million US cases annually). Partnered with GSK, Spero is positioned to receive significant milestone payments and royalties while maintaining a low operational burn rate and a robust cash runway extending into 2028.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$4.00

High · most bullish analyst$4.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.06

Utebzi's commercial launch is slower than expected due to restrictive payer coverage or slow clinical adoption. Spero fails to secure attractive new pipeline candidates, leaving the company solely dependent on lumpy milestone payments and a slow-growing royalty stream.

Base CaseCentral scenario

$4.00

Matches the consensus mean

GSK successfully launches Utebzi in the US by late 2026, triggering near-term commercial milestones and steady royalty streams. Spero leverages its cash runway into 2028 to identify and acquire new clinical-stage assets, transitioning from a single-product story to a diversified rare disease and anti-infective platform.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

FDA approval of Utebzi (tebipenem pivoxil) on June 17, 2026, significantly de-risks the regulatory profile.
Strong global commercial partnership with GSK, which holds exclusive rights (excluding select Asian territories) and handles commercialization.
Robust balance sheet with $56.1 million in cash as of March 31, 2026, providing a runway into 2028.
Potential for up to $525 million in total milestones from GSK, including a $150 million milestone tied to first sales.

Key Investment Risks

High reliance on a single approved asset (Utebzi) and the commercial execution of partner GSK.
Limited internal clinical pipeline after the discontinuation of SPR206 and SPR720.
Risk of slow market adoption or restrictive formulary positioning for Utebzi.

Thesis Invalidation Triggers

GSK delays or suspends the US commercial launch of Utebzi past 2026.
Initial commercial sales of Utebzi severely underperform consensus expectations.
Significant unexpected safety signals emerge post-marketing, leading to restrictive labeling or recall.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.